HomeFileStructural heart disease

Structural heart disease

TAVR Durability at 5 Years in Intermediate Risk Patients

TAVR has been shown beneficial in patients across the risk spectrum. The PARTNER 2 SAPIEN 3 (P2S3i)...

Is Edge-to-Edge Treatment with PASCAL Effective at 3 Years?

Mitral regurgitation is the most common valvular heart disease. Its cause is most frequently functional or secondary...

Cerebrovascular Events in the COAPT Study

Transcatheter edge-to-edge repair (TEER) with MitraClip has demonstrated its benefit compared with complete guideline-directed medical therapy (GDMT),...

Transcatheter Mitral Valve Replacement vs. Medical Therapy

Mitral valve regurgitation (MR) is a common cause behind heart failure and is associated to hospitalization for...

Aortic Stenosis and Cardiogenic Shock: Is TAVR an Option?

Cardiogenic shock (CS) in a setting of aortic stenosis is associated with high mortality rates. In consequence,...

A New Alternative for the Treatment of Heart Failure: Left Atrial to Coronary Sinus Shunt with the APTURE Device

ALT FLOW device for left atrial to coronary sinus shunting in symptomatic heart failure patients. In the treatment...

COAPT: Nutritional Condition Is an Important Factor in Edge-to-Edge Treatment

Heart failure is strongly associated with malnutrition or poor nutrition, which has been linked to increased mortality...

VASC-OBSERVANT II Substudy: Impact of Vascular Complications after TAVR

At present, transcatheter aortic valve replacement (TAVR) has become increasingly common to treat severe symptomatic aortic stenosis,...